For the second time in less than three months, the US Food and Drug Administration has taken the extraordinary step of publicly refuting a sponsor’s upbeat claims about the efficacy of an investigational drug.
On 17 May, the agency announced that two trials of CytoDyn, Inc.’s leronlimab “do not support the...